PK and Tolerability of CKD-348(2) vs Co-administration of Components

Phase 1, randomised, open-label trial of Levamlodipine, telmisartan, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jun 2021; status: completed.